Bristol-Myers Squibb Co (BMY)
55.26
+0.94
(+1.73%)
USD |
NYSE |
Nov 04, 13:04
Bristol-Myers Squibb Enterprise Value: 151.89B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 151.89B |
| October 31, 2024 | 154.83B |
| October 30, 2024 | 148.52B |
| October 29, 2024 | 148.20B |
| October 28, 2024 | 148.48B |
| October 25, 2024 | 147.02B |
| October 24, 2024 | 149.05B |
| October 23, 2024 | 149.34B |
| October 22, 2024 | 148.73B |
| October 21, 2024 | 147.44B |
| October 18, 2024 | 149.67B |
| October 17, 2024 | 149.59B |
| October 16, 2024 | 149.97B |
| October 15, 2024 | 148.73B |
| October 14, 2024 | 148.55B |
| October 11, 2024 | 147.60B |
| October 10, 2024 | 148.00B |
| October 09, 2024 | 148.82B |
| October 08, 2024 | 148.17B |
| October 07, 2024 | 150.11B |
| October 04, 2024 | 151.17B |
| October 03, 2024 | 151.66B |
| October 02, 2024 | 150.76B |
| October 01, 2024 | 149.02B |
| September 30, 2024 | 146.67B |
| Date | Value |
|---|---|
| September 27, 2024 | 149.00B |
| September 26, 2024 | 147.40B |
| September 25, 2024 | 147.06B |
| September 24, 2024 | 149.07B |
| September 23, 2024 | 147.18B |
| September 20, 2024 | 145.96B |
| September 19, 2024 | 145.17B |
| September 18, 2024 | 146.63B |
| September 17, 2024 | 146.13B |
| September 16, 2024 | 147.14B |
| September 13, 2024 | 145.40B |
| September 12, 2024 | 143.59B |
| September 11, 2024 | 144.30B |
| September 10, 2024 | 145.70B |
| September 09, 2024 | 144.12B |
| September 06, 2024 | 144.52B |
| September 05, 2024 | 146.75B |
| September 04, 2024 | 147.08B |
| September 03, 2024 | 148.21B |
| August 30, 2024 | 147.06B |
| August 29, 2024 | 146.59B |
| August 28, 2024 | 145.25B |
| August 27, 2024 | 143.35B |
| August 26, 2024 | 143.59B |
| August 23, 2024 | 143.33B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
84.40B
Minimum
Nov 05 2019
202.63B
Maximum
Dec 02 2022
163.11B
Average
165.68B
Median
Jun 02 2020
Enterprise Value Benchmarks
| Amgen Inc | 222.98B |
| Johnson & Johnson | 400.99B |
| Eli Lilly and Co | 805.11B |
| Merck & Co Inc | 284.75B |
| Pfizer Inc | 221.03B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.211B |
| Revenue (Quarterly) | 11.89B |
| Total Expenses (Quarterly) | 9.72B |
| EPS Diluted (Quarterly) | 0.60 |
| Gross Profit Margin (Quarterly) | 75.13% |
| Profit Margin (Quarterly) | 10.18% |
| Earnings Yield | -6.50% |
| Operating Earnings Yield | 6.49% |
| Normalized Earnings Yield | 2.889 |